Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs IONQ Inc (IONQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs IONQ Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while IONQ Inc trades at $39.86 (market cap $15.98B). The key difference: IONQ Inc is the larger of the two by market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, IONQ Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and IONQ Inc for 33 Days on average.
| HALO | IONQ | |
|---|---|---|
Market Cap | $12.58B | $15.98B |
Volume | 2,179,278 | 22,848,240 |
Sector | Health | Technology |
52-Week High | $115.22 | $82.09 |
52-Week Low | $61.63 | $26.59 |
Typical Hold Time | 1 Days | 33 Days |
Enterprise Value | $14.49B | $13.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
IONQ trades at $39.63, down 4.14% today, with a bearish technical signal despite oscillators showing some bullish momentum. The company reported revenue of $130.02M in 2025 but posted a net loss of $510.38M, reflecting negative profit margins of -553.27%. Recent earnings showed mixed results with a Q2 2026 miss after two consecutive beats. Analyst sentiment remains divided with a 50/50 buy/hold split but a consensus price target of $62.75 suggesting significant upside potential from current levels.
The outlook for IONQ hinges on scaling quantum computing technology to justify its premium valuation (P/S 54.74). While strong revenue growth projections and strategic partnerships offer long-term potential, investors face substantial risks from persistent losses, cash burn, and intense competition in the emerging quantum computing sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →
